About Admetsys

Admetsys has developed a first-of-its-kind artificial pancreas for hospital and surgical care, leveraging

adaptive learning algorithms and counterbalancing treatment of insulin and glucose.

97% Control

between 80-125 mg/dL

0% Hypoglycemia

< 70 mg/dL

2.5 hrs Mean Time

to Normoglycemia

Nurses:

Frequent measures are critical for a clear glycemic picture.

In one retrospective study, average

frequency was 2.6 hours despite

a goal of hourly checks.

A 12-minute measurement delay (from hourly)

was associated with 67% of severe

hypoglycemia episodes.

86% of nurses in one study felt that an easier or more automated

form of measurement was needed.

Administrators:

Proper diabetic control:

Lowers Legal

& Regulatory Risk

Lowers Costs

Increases

Standard of Care

Improves

Reimbursement Rates

Contact Us

Want to get involved and be a part of Admetsys?

Join us as an Advocate, Advisor or Investor.

We'll never send you spam.

We hate spam.

Stay tuned.

Diabetic treatment.

Revolutionized.

For people at diabetic risk, glucose control is at its most

crucial while in hospital or surgery. Correcting abnormal

glucose levels and keeping them normal speeds recovery,

prevents infection, and reduces complications. To date,

this has been difficult, highly labor-intensive, and imprecise.

That is about to change.

Admetsys has conducted 3 clinical trials with outstanding results:

Watch the video to Learn More

PHYSICIANS

ABOUT

NURSES

ADMINISTRATORS

INVESTORS

CONTACT US

Source: American Diabetes Association (ADA).

Submitting Form...

The server encountered an error.

Form received.

Investors:

The market is in the need of better solution.

$245 Billion – 2012 Estimated Cost of Diabetes in USA

41% Increase over 5 years

(2007 to 2012)

43% of the total medical cost

– hospital inpatient care

Physicians:

Improved glycemic control has been associated with:

Overall In-Hospital

Mortality

Reduction in

Complications

Reduction in ICU Length of Stay

® ™ © 2016 Admetsys. All Rights Reserved. Admetsys™, Metabolic Autopilot™ and Smart Pancreas™ are trademarks of Admetsys.

Device not yet cleared for commercial sale. Limited in the USA to investigational use.